ViewRay sets the price range for its pending initial public offering, which would fetch $52 million at the midpoint.
ViewRay today set the terms for its pending initial public offering, saying it plans to float 4 million shares at $12 to $14 apiece.
At the midpoint of the range, the MRI-guided radiation therapy maker's IPO would fetch $52 million.
Varian Medical Systems says it plans to boost its footprint in Atlanta with a new facility there, adding 100 new jobs in the process.
ViewRay registers for an initial public offering worth up to $69 million for its MRIdian cancer detection and radiation treatment device.
ViewRay last week said it plans to raise up to $69 million in an initial public offering for its MRIdian system, which it bills as "the 1st and only MRI-guided radiation therapy system that images and treats cancer patients simultaneously."
Mevion Medical looks to go public with a $69 million stock offering as it gears up to scale its proton therapy device.
Mevion Medical registered for a $69 million initial public offering as it gears up to commercialize its proton therapy system.
Group purchasing organizations Premier selects radiosurgery devices maker Accuray for an exclusive 3-year contract.
Accuray (NSDQ:ARAY) touted landed a new exclusive contract to offer its CyberKnife M6 and TomoTherapy HDA devices to members of Premier Inc. at special rates.
Accuray says it's agreed to settle the patent infringement and poaching lawsuits it had going against Best Medical.
Varian passes on an acquisition option as Augmenix closes a Series D funding round with $10.8 million raised in support of its Space OAR hydrogel for protecting the rectum during prostate radiation therapy.
Massachusetts-based Augmenix is hoping it can make it to the U.S. market with the $10.8 million funding round it just closed, the company said this month.